Haima Therapeutics
Haima Therapeutics is a pre-clinical stage biopharma company focused on developing cell-inspired therapies for the treatment of bleeding and various blood-related diseases. Their lead technology, SynthoPlate, is a novel, fully-synthetic hemostatic agent designed to mitigate bleeding by enhancing the body's natural clotting mechanisms at the site of injury.
Haima Therapeutics
11000 Cedar Ave., Ste 280, Cleveland, OH 44106
What We Do
Platelet-inspired Platform Technology
Haima’s platelet-inspired platform technology leverages the natural functions of platelets to deliver bioactive cargo on a nanoparticle platform, providing tailored therapies for various clinical scenarios.
SynthoPlate
SynthoPlate is an IV-injectable hemostatic agent that mimics and amplifies platelet functions to stop bleeding in patients with low platelet counts or dysfunction.
Biologics
News & Updates
Announcement of new appointments to the executive team.
Involvement in a significant project aimed at developing blood substitutes.